ahlam1399
03-09-2016, 05:00 AM
Sarepta says yet to receive new date for panel review of muscle wasting drug
(Reuters) - Drug developer Sarepta Therapeutics Inc said it had **t received a rescheduled date for the review of its drug for a rare muscle wasting disorder by an FDA advisory panel and would slash about 17 percent of its workforce.
http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/1/rc.img (http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/1/rc.htm)
http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/2/rc.img (http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/2/rc.htm)
http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/3/rc.img (http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/3/rc.htm)
http://da.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/a2.img (http://da.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/a2.htm)
http://adchoice.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/ach.img (http://adchoice.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/ach.htm)http://pi.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/a2t.imghttp://pi2.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e203ec5/sc/32/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=Sk1RNuZD7d8:62ICHI7-Jyo:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Sk1RNuZD7d8:62ICHI7-Jyo:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=Sk1RNuZD7d8:62ICHI7-Jyo:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Sk1RNuZD7d8:62ICHI7-Jyo:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=Sk1RNuZD7d8:62ICHI7-Jyo:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/Sk1RNuZD7d8
(Reuters) - Drug developer Sarepta Therapeutics Inc said it had **t received a rescheduled date for the review of its drug for a rare muscle wasting disorder by an FDA advisory panel and would slash about 17 percent of its workforce.
http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/1/rc.img (http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/1/rc.htm)
http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/2/rc.img (http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/2/rc.htm)
http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/3/rc.img (http://rc.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/rc/3/rc.htm)
http://da.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/a2.img (http://da.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/a2.htm)
http://adchoice.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/ach.img (http://adchoice.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/ach.htm)http://pi.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/a2t.imghttp://pi2.feedsportal.com/r/247394124034/u/49/f/654207/c/35217/s/4e203ec5/sc/32/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e203ec5/sc/32/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=Sk1RNuZD7d8:62ICHI7-Jyo:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Sk1RNuZD7d8:62ICHI7-Jyo:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=Sk1RNuZD7d8:62ICHI7-Jyo:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=Sk1RNuZD7d8:62ICHI7-Jyo:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=Sk1RNuZD7d8:62ICHI7-Jyo:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/Sk1RNuZD7d8